The test measures a relative concentration of neutralizing antibodies (NAbs) in patients recovering from COVID-19. It has received U.S. FDA Emergency Use Authorization (EUA) as a serology test for neutralizing antibodies to identify an adaptive immune response in individuals with recent and prior SARS-CoV-2 infections. The kit is also CE marked (Europe) and has received HSA provisional approval (Singapore), ANVISA in Brazil, and ANMAT in Argentina.
“We are excited to team up with EUROIMMUN to distribute GenScript’s cPass SARS-CoV-2 Neutralization Antibody Detection Kit. We believe this collaboration can further enhance the significant contribution cPass has provided to the fight against COVID-19 and will continue to play an important role as we move towards normalcy,” said Dr. Michael Lau, senior director of corporate development for GenScript USA.
“With the addition of the cPass SARS CoV-2 Neutralization Antibody Detection Kit to our SARS-CoV-2 portfolio, EUROIMMUN is well-positioned to assist our customers and their patients in assessing their adaptive immune response,” said Greg Stock, general manager of EUROIMMUN US. “As diagnostic testing, clinical recommendations, and the virus itself all continue to evolve, we remain 100 percent committed to empowering clinicians and laboratories with high-quality diagnostic tests and automation that aid in the fight against COVID-19.”
About EUROIMMUN
As one of the leading manufacturers of medical laboratory diagnostics worldwide,…